



## **The 2022 American Society of Clinical Oncology (ASCO) Annual meeting; Chicago, Illinois (Hybrid): Eisai Inc. Sponsored Research**

Please see the listing of Eisai Inc. sponsored research presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting below.

### **RENAL CELL CARCINOMA**

Voss MH, Powles T, McGregor B, et al. Impact of Subsequent Therapies in Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Lenvatinib Plus Pembrolizumab (LEN + PEMBRO) or Sunitinib (SUN) in the CLEAR Study. Poster presented at: The American Society of Clinical Oncology annual meeting; June 3–7, 2022; Chicago, IL, USA, and in Virtual Format.

### **ADVANCED ENDOMETRIAL CANCER**

Makker V, Columbo N, Santin A, et al. Efficacy of Next Line of Therapy After Treatment With Lenvatinib in Combination With Pembrolizumab vs Treatment of Physician's Choice in Patients With Advanced Endometrial Cancer: Exploratory Analysis of Study 309/KEYNOTE-775. Poster presented at: The American Society of Clinical Oncology annual meeting; June 3–7, 2022; Chicago, IL, USA, and in Virtual Format.

### **UNRESECTABLE HEPATOCELLULAR CARCINOMA**

Kudo M, Qin S, Piscaglia F, et al. Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in REFLECT. Poster presented at: The American Society of Clinical Oncology annual meeting; June 3–7, 2022; Chicago, IL, USA, and in Virtual Format.

### **OVARIAN CANCER**

Nishio S, Yunokawa M, Matsumoto K, et al. Safety and Efficacy of MORAb-202 in Patients With Platinum-Resistant Ovarian Cancer (PROC): Results From the Expansion Part of a Phase 1 Trial. Poster presented at: The American Society of Clinical Oncology annual meeting; June 3–7, 2022; Chicago, IL, USA, and in Virtual Format.

### **ADDITIONAL RESEARCH**

Hayatao S, Hamuro L, Nomoto M, et al. Dose Optimization for MORAb-202, an Antibody–Drug Conjugate Highly Selective for Folate Receptor-Alpha, Using Population Pharmacokinetic and Exposure–Response Efficacy and Safety Analyses. Poster presented at: The American Society of Clinical Oncology annual meeting; June 3–7, 2022; Chicago, IL, USA, and in Virtual Format.

**IMPORTANT INFORMATION - PLEASE READ:**

If you would like a full copy of the publication(s) listed above, please submit your request via the medical information inquiry form available on our medical information website at [www.eisaimedicalinformation.com/oncology/medicalinquiry](http://www.eisaimedicalinformation.com/oncology/medicalinquiry). Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at [esi\\_oncmedinfo@eisai.com](mailto:esi_oncmedinfo@eisai.com) or call 1-888-274-2378.